Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Trial Profile

Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Ganitumab (Primary) ; Rilotumumab (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 03 Jun 2014 Pharmacokinetic substudy results for rilotumumab and placebo arms presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Oct 2013 Primary endpoint 'Overall-survival-duration' has not been met.
    • 08 Mar 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top